{"type":"trials","record":{"id":42231,"source_id":"clinicaltrials-gov","external_id":"NCT05539235","title":"Efficacy and Safety of Intravitreal Conbercept With Modified Treat-and-Extend Regimens in Exudative AMD","brief_summary":"This is a prospective study. Data from patients diagnosed with nAMD who have never received related treatment were collected. Treatment was an intravitreal injection of 0.5 mg conbercept using modified \"T\\&E\" treatment plans. After three months of monthly intravitreal injections, the patients were randomly divided into two groups, and the degree of adjustment of the injection interval was divided into two weeks and four weeks. Unlike the ALTAIR study, we cancel the maintenance criteria of classical T\\&E regimens. The best-corrected visual acuity (BCVA), central retinal thickness (CRT), last injection interval, and the number of injections were recorded at 3, 6, 12, and 24 months to evaluate treatment efficacy.","overall_status":"Unknown","phases":["PHASE2","PHASE3"],"study_type":"INTERVENTIONAL","sponsor":"First Affiliated Hospital of Chongqing Medical University","enrollment":60,"countries":["China"],"start_date":"2018-11-12","completion_date":"2024-08-01","last_update_date":"2022-09-14","source_url":"https://clinicaltrials.gov/study/NCT05539235","editorial_summary":"A registered PHASE2, PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Unknown. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":"IIT-A","age_range":"55 Years to 90 Years","comparator":null,"organization":"First Affiliated Hospital of Chongqing Medical University","interventions":["different degrees of adjustment of the injection interval"],"registry_source":"ClinicalTrials.gov","outcome_measures":["mean change of the best-corrected visual acuity — baseline, every time before pre-intervention","mean change of central retinal thickness — baseline, every time before pre-intervention","mean time of last injection interval — up to 2 years","mean number of injections — up to 2 years","the rate of complications or adverse reactions — up to 2 years"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE","source_has_results":false},"controlled_terms":["Exudative Age-Related Macular Degeneration","different degrees of adjustment of the injection interval"],"relevance_confidence":60,"source_quality_score":100,"freshness_score":50,"publication_state":"published","match_explanation":"Source terminology contains: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct05539235","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2018-11-12 to 2024-08-01","comparator":null,"confidence":"structured-source","population":"ALL · 55 Years to 90 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.938Z","intervention":["different degrees of adjustment of the injection interval"],"participants":60,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE2, PHASE3","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["mean change of the best-corrected visual acuity — baseline, every time before pre-intervention","mean change of central retinal thickness — baseline, every time before pre-intervention","mean time of last injection interval — up to 2 years","mean number of injections — up to 2 years","the rate of complications or adverse reactions — up to 2 years"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Source terminology contains: age-related macular degeneration.","Source terminology supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["controlled terminology","controlled context","study type"],"relevance_score":60,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/42231","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}